Nature Reviews Drug Discovery contents February 2018 Volume 17 Number 2 pp 79-150

If you are unable to see the message below, click here to view.
 

Advertisement
Analyze Large and Small Molecule Inhibitors in a Single Homogeneous Assay Want to analyze downstream cell signaling events impacted by both large and small molecule inhibitors in a single assay? Learn about a no-wash platform for screening antibodies and small molecule inhibitors, in this example used to characterize chemokine receptor inhibitors.  Download Application Note
TABLE OF CONTENTS
February 2018 Volume 17 Number 2		Advertisement
2016 2-year Impact Factor 57.000 Journal Metrics 2-year Median 38	In this issue Comment News and Analysis Research Highlights Perspectives Reviews Correspondence   Also this month  Featured article: Automating drug discovery Gisbert Schneider	To mark the 100th anniversary of the 1918 influenza pandemic, Nature Reviews Microbiology presents a collection including Reviews and research articles from across Nature Research to showcase the latest advances in our understanding of influenza virus biology, evolution and adaptation, and advances in surveillance and drug and vaccine development. Access the collection online.
Subscribe   Facebook   RSS   Recommend to library   Twitter
Advertisement
Discover a new path to your success via Human Data Science. IMS Health and Quintiles are now IQVIA™ - created to advance your pursuits of human science by unleashing the power of data science and human ingenuity. We are here to help you find solutions to drive healthcare forward. Join the journey today.
Advertisement
BIOPHARMA DEALMAKERS Company Profiles and Partnering Opportunities
Advertisement
Nature Collection: Mitochondria and the heart Nature Reviews Cardiology brings together a collection of articles from Nature Research journals highlighting the importance of mitochondria in the heart and the new opportunities for mitochondria-targeted therapies in cardiac diseases. Access here >> Produced with support from:  Stealth BioTherapeutics
Advertisement
nature.com webcasts Springer Nature presents a custom webcast on: Untangling Neurodegenerative Diseases using Cryo-Electron Microscopy Date: Wednesday, February 7, 2018 Register for the webcast and live Q&A session >> Sponsored by: Thermo Fisher Scientific
Comment: Regulatory policy for the development of targeted therapies for low-frequency molecular subtypes of disease Robert N. Schuck, Michael Pacanowski, Janet Woodcock & Issam Zineh p79 | doi:10.1038/nrd.2017.231 Numerous challenges arise when developing targeted therapies for diseases comprising low-frequency molecular subtypes. In this article, we describe a pragmatic, science-based regulatory policy for the development and approval of targeted therapies in such cases. Full Text | PDF
NEWS AND ANALYSIS		Top
2017 FDA drug approvals Asher Mullard p81 | doi:10.1038/nrd.2018.4 The FDA approved 46 new drugs last year, the highest total in more than two decades. PDF
NEWS IN BRIEF Top product sales forecasts for 2018 Asher Mullard p86 | doi:10.1038/nrd.2018.15 PDF
Pfizer exits neuroscience Asher Mullard p86 | doi:10.1038/nrd.2018.16 PDF
EMA recommended 35 new drugs in 2017 Asher Mullard p86 | doi:10.1038/nrd.2018.17 PDF
BIOBUSINESS BRIEFS Market watch: 2017 FDA drug approvals: number rebounds but average value slips Mathias Baedeker, Michael Ringel, Valery Panier & Ulrik Schulze p87 | doi:10.1038/nrd.2018.2 PDF
AN AUDIENCE WITH Morgan Sheng p88 | doi:10.1038/nrd.2017.271 PDF
FROM THE ANALYST'S COUCH Biopharma deal-making in 2017 Amanda Micklus & Steven Muntner p91 | doi:10.1038/nrd.2018.1 This article analyses merger and acquisition (M&A) activity and partnerships in the biopharma industry in 2017, highlighting trends and major deals. PDF
RESEARCH HIGHLIGHTS   Top Gene therapy: Reprogramming α-cells reverses diabetes p93 | doi:10.1038/nrd.2018.7 PDF Regenerative medicine: Cholesterol clearance restores remyelination p94 | doi:10.1038/nrd.2018.12 PDF Pharmacogenomics: Know your GPCR mutations (and target them right) p94 | doi:10.1038/nrd.2018.13 PDF Gene therapy: CRISPR therapies — making the grade not the cut p95 | doi:10.1038/nrd.2018.3 PDF Neurodegenerative diseases: Inflammasome protein seeds plaques in Alzheimer disease p96 | doi:10.1038/nrd.2018.5 PDF   IN BRIEF Cancer: Anticancer effects of alcohol abuse drug | Immunotherapy: Oncolytic virotherapy enables checkpoint blockade | Inflammation: Microbiome manipulation ameliorates colitis PDF Drug Discovery JOBS of the week Senior Scientist (Bioscience) Sygnature Discovery Post Doc Fellow – Structural Biology and Drug Discovery The H. Lee Moffitt Cancer Postdoctoral Fellow University Health Network (Toronto) Postdoc University of Virginia PhD Students and Postdoctoral Scientists University Medical Center Freiburg More Science jobs from Drug Discovery EVENT 5th NovAliX Conference - Biophysics in Drug Discovery 2018 13.07.18 Boston, USA More science events from
Advertisement
Do you have a career question?  The Naturejobs podcast features one-on-one Q&As, panel discussions and other exclusive content to help scientists with their careers. Hosted on the Naturejobs blog, the podcast is also available on iTunes and Soundcloud.  Listen today!
PERSPECTIVES		Top
INNOVATION Automating drug discovery Gisbert Schneider p97 | doi:10.1038/nrd.2017.232 Advances in areas such as microfluidics-assisted chemical synthesis and biological testing, as well as in artificial intelligence systems, are increasingly providing opportunities to introduce greater automation into the small-molecule drug discovery process. Schneider highlights approaches and technologies that seem poised to be implemented robustly by medicinal chemists in the near future and analyses the challenges for their more widespread application Abstract | Full Text | PDF
REVIEWS		Top
Mechanistic enzymology in drug discovery: a fresh perspective Geoffrey A. Holdgate, Thomas D. Meek & Rachel L. Grimley p115 | doi:10.1038/nrd.2017.219 Understanding the role of enzymes in disease states and the implementation of strategies to modulate their activities for therapeutic benefit remains a key focus for drug discovery. Here, Holdgate and colleagues assess the benefits of conducting and applying high-quality mechanistic enzymology studies throughout a drug-discovery programme and assess the value of combining such knowledge with orthogonal biophysical methods. Abstract | Full Text | PDF
Emptying the stores: lysosomal diseases and therapeutic strategies Frances M. Platt p133 | doi:10.1038/nrd.2017.214 Lysosomal storage disorders (LSDs) are rare, inherited metabolic disorders that result from defects in lysosomal function, for which treatment options are limited. Here, Platt provides an overview of LSDs, approved and potential therapeutic approaches and agents currently in development. The challenges associated with LSD diagnosis, drug development and treatment are discussed. Abstract | Full Text | PDF
CORRESPONDENCE		Top
A dynamic map for learning, communicating, navigating and improving therapeutic development John Wagner, Andrew M. Dahlem, Lynn D. Hudson, Sharon F. Terry, Russ B. Altman, C. Taylor Gilliland, Christopher DeFeo & Christopher P. Austin p150 | doi:10.1038/nrd.2017.217 Full Text | PDF | Supplementary information
Corrigendum: 2017 FDA drug approvals Asher Mullard p150 | doi:10.1038/nrd.2018.18 Full Text | PDF
Advertisement
nature.com webcasts Springer Nature presents a custom webcast on: Transforming Translational Research: CANscript™ - A Better Predictive Model For Oncology Date: Tuesday, February 20, 2018  Register for the webcast and live Q&A session  Sponsored by:  Mitra Biotech
Natureevents is a fully searchable, multi-disciplinary database designed to maximise exposure for events organisers. The contents of the Natureevents Directory are now live. The digital version is available here. Find the latest scientific conferences, courses, meetings and symposia on natureevents.com. For event advertising opportunities across the Nature Publishing Group portfolio please contact natureevents@nature.com More Nature Events

You have been sent this Table of Contents Alert because you have opted in to receive it. You can change or discontinue your e-mail alerts at any time, by modifying your preferences on your nature.com account at: www.nature.com/myaccount (You will need to log in to be recognised as a nature.com registrant). For further technical assistance, please contact our registration department For print subscription enquiries, please contact our subscription department For other enquiries, please contact our feedback department Springer Nature | One New York Plaza, Suite 4500 | New York | NY 10004-1562 | USA Springer Nature's worldwide offices: London - Paris - Munich - New Delhi - Tokyo - Melbourne San Diego - San Francisco - Washington - New York - Boston Macmillan Publishers Limited is a company incorporated in England and Wales under company number 785998 and whose registered office is located at The Campus, 4 Crinan Street, London, N1 9XW. © 2018 Macmillan Publishers Limited, part of Springer Nature. All Rights Reserved.